Physician profile
Neil E Padgett
NPI 1831181833
$13,308.16
in general payments reported to CMS, 2019-2025
68 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $1,955 · 2021: $2,063 · 2022: $2,052 · 2023: $2,043 · 2024: $1,959 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,886.16 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,068.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,083.34 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $933.72 | 2020-2025 | |
| Lilly USA, LLC | $904.07 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $830.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $823.14 | 2019-2025 | Jardiance |
| Amgen INC. | $595.48 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Merck Sharp & Dohme LLC | $475.57 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $408.72 | 2020-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $404.69 | 2020-2023 | Xarelto |
| Daiichi Sankyo INC. | $339.64 | 2019-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.79 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $279.66 | 2019-2025 | Freestyle Libre 3 |
| Viiv Healthcare Company | $260.59 | 2020 | |
| Allergan, INC. | $232.18 | 2019-2020 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.